Thyroid: Effects of radioactive iodine therapy on ovarian function and fertility in women with thyroid cancer.

Thyroid cancer is one of the most common cancers among adolescents and young people and has increased rapidly over the past three decades.
surgery is standard treatment for patients with differentiated thyroid cancer (DTC) and, if necessary, radioactive iodine (RAI) treatment.
, a study published recently in Theyroid, an authoritative journal in the field of thyroid disease, aims to assess the possible effects of RAI therapy on ovarian function and fertility in women.
researchers systematically retrieved the PubMed, Embase, and Web of Science databases as of January 2020.
addition, the researchers conducted a meta-analysis of post-RAI antimuller (AMH) levels, AMH levels before and after RAI, and pregnancy rates in patients with thyroid cancer who received RAI and did not receive RAI.
the meta-analysis, a total of 36 documents were eligible for screening, including 22 studies.
most studies are retrospective designs.
menstrual insanity in the first year after rai was 12 per cent, up to 31 per cent.
the first year after RAI, about 8% to 16% of patients experienced ad after menoage.
women who received RAI treatment (with a medium dose of 3700 MBq (range 1110-40700 MBq) were slightly younger in menopause than women who did not receive RAI treatment, aged 51 and 49.5 years, respectively.
AML concentration was 1.79 ng/ml after RAI in seven studies.
, four studies reported AMH concentrations before and after RAI, with an average difference of 1.50 ng/ml.
, meta-analysis showed no reduction in pregnancy risk in patients receiving RAI.
meta-analysis showed a significant decrease in AMH levels after RA I treatment, most studies showed that RAI treatment in DTC patients was not associated with long-term pregnancy rates.
need to conduct forward-looking studies to confirm these results.
.